Skip to main content
. Author manuscript; available in PMC: 2017 Nov 8.
Published in final edited form as: Oral Oncol. 2015 Dec 15;53:74–79. doi: 10.1016/j.oraloncology.2015.11.014

Table 2.

Treatment-related adverse events by dose level and symptom.

IPI-926 dose level 130 mg 160 mg Total
Evaluable patients 3 6 9
Patients with a DLT 0 0 0
Grade 1 2 3 1 2 3 1 2 3
Attributed to IPI-926
  Nausea 2 0 0 1 0 0 3 0 0
  Muscle Cramps 1 0 0 1 0 0 2 0 0
  Fatigue 0 1 0 1 0 0 1 1 0
  Alopecia 1 0 0 0 0 0 1 0 0
  Dysguesia 0 0 0 1 0 0 1 0 0
  Elevated AST 0 0 0 1 0 0 1 0 0
Attributed to Cetuximab
  Acneiform rash 2 0 0 2 0 0 4 0 0
  Dry skin/desquamation 0 0 0 2 0 0 2 0 0
  Infusion reaction 0 0 0 0 0 1* 0 0 1
  Diarrhea 0 0 0 1 0 0 1 0 0
  Mucositis 0 0 0 1 0 0 1 0 0
  Hypomagnesemia 0 0 0 1 0 0 1 0 0
*

The patient with a grade 3 infusion reaction to cetuximab was removed from study following his loading dose of cetuximab and never received IPI-926.